PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Cemiplimab→

Cemiplimab PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
1801342-60-8
Molecular formula
Not available
Molecular weight
Not available
Drug class
Programmed cell death protein 1 (PD-1) immune-checkpoint inhibitormonoclonal antibody
Mechanism of action
Binds PD-1 on T cells and blocks interaction with PD-L1 and PD-L2, releasing PD-1-mediated inhibition of antitumour T-cell activity and restoring immune recognition and killing of tumour cells.
Indications / reported uses
  • Treatment of metastatic or locally advanced cutaneous squamous cell carcinoma (CSCC) in patients who are not candidates for curative surgery or radiation
  • Treatment of locally advanced or metastatic basal cell carcinoma (BCC) after hedgehog pathway inhibitor therapy or when such therapy is inappropriate
  • Treatment of selected advanced non-small-cell lung cancer (NSCLC) settings; combination and biomarker criteria depend on current product label and jurisdiction

Sources: US DailyMed — LIBTAYO (cemiplimab-rwlc) · US FDA prescribing information · FDA product information

View request basketPrefer email? info@toxwriter.com
PDE / ADE derivationOEL derivationOEB / OHC banding
Assessment scope

PDE/ADE and OEL/OEB assessment

ToxWriter provides project-specific support for Cemiplimab PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Cemiplimab Permitted Daily Exposure (PDE) report (the Cemiplimab PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Cemiplimab Occupational Exposure Limit (OEL) report (the Cemiplimab OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.